J Cancer 2019; 10(14):3172-3178. doi:10.7150/jca.30257 This issue Cite

Research Paper

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer

Youjin Kim1,2*, Sun-ju Byeon3,4*, Joonyoung Hur1, Kangkook Lee1, Dongin Kim5, Jin-Hyung Ahn5, Sang Hoon Lee5, Weon-Kyoo You5, Seung Tae Kim1, Se Hoon Park1, Won Ki Kang1, Kyoung-Mee Kim3✉, Jeeyun Lee1✉

1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2. Division of Hematology-Oncology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
3. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4. Department of Pathology, Hallym University Dongtan Sacred Heart Hospital, Korea
5. ABL Bio, Korea
*Equal contributing authors

Citation:
Kim Y, Byeon Sj, Hur J, Lee K, Kim D, Ahn JH, Lee SH, You WK, Kim ST, Park SH, Kang WK, Kim KM, Lee J. High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. J Cancer 2019; 10(14):3172-3178. doi:10.7150/jca.30257. https://www.jcancer.org/v10p3172.htm
Other styles

File import instruction

Abstract

Background: Emerging evidence suggests that delta-like ligand 4 (DLL4) and other members of the Notch pathway may offer new targets for development of anti-angiogenesis drugs for the treatment of several tumor types. However, the role of DLL4 in gastric cancer (GC) remains unclear. In this study, we investigated the impact of DLL4 overexpression on recurrence and survival in gastric cancer (GC) patients.

Methods: DLL4 expression levels were evaluated by immunohistochemistry in tissue samples from 336 GC patients. Samples were classified into high and low DLL4 expression according to a cut-off of 50% positively stained cells. The correlation between DLL4 expression and clinicopathological parameters, disease-free survival (DFS), and overall survival (OS) were statistically analyzed.

Results: High DLL4 expression was observed in 67 (19.9%) of the 336 GC patients. After a median follow-up duration of 54.97 months [95% confidence interval (CI), 52.40-57.55 months), patients at stage II-IV with high DLL4 expression showed significantly poorer DFS compared with those at the same stage but with low DLL4 expression [not reached (NR) for both cohorts, hazard ratio (HR) 0.73 (95% CI, 0.38-1.40); p = 0.007]. Likewise, GC patients with high DLL4 expression had a significantly shorter OS following curative surgery compared to those with low DLL4 expression [NR for both groups, HR 0.56 (95% CI, 0.32-0.96; p = 0.002]. High DLL4 expression had a greater influence on DFS in stage IIIb/IV patients than in patients at early stages [34.87 vs. 10.1 months; HR, 0.44 (95% CI, 0.19-0.96); p = 0.004]. Moreover, stage IIIb/IV patients with high DLL4 expression had a significantly shorter OS after surgery than those with low DLL4 expression [58.87 vs. 16.93 months, HR 0.39 (95% CI, 0.16-0.99), p = 0.001).

Conclusion: High DLL4 expression was observed in 19.9% of GC patients and was significantly associated with poor survival following curative surgery. Given its prevalence in the GC cohort with a poor prognosis, DLL4 is a potential therapeutic target.

Keywords: DLL4, Gastric cancer, anti-angiogenesis


Citation styles

APA
Kim, Y., Byeon, S.j., Hur, J., Lee, K., Kim, D., Ahn, J.H., Lee, S.H., You, W.K., Kim, S.T., Park, S.H., Kang, W.K., Kim, K.M., Lee, J. (2019). High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. Journal of Cancer, 10(14), 3172-3178. https://doi.org/10.7150/jca.30257.

ACS
Kim, Y.; Byeon, S.j.; Hur, J.; Lee, K.; Kim, D.; Ahn, J.H.; Lee, S.H.; You, W.K.; Kim, S.T.; Park, S.H.; Kang, W.K.; Kim, K.M.; Lee, J. High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. J. Cancer 2019, 10 (14), 3172-3178. DOI: 10.7150/jca.30257.

NLM
Kim Y, Byeon Sj, Hur J, Lee K, Kim D, Ahn JH, Lee SH, You WK, Kim ST, Park SH, Kang WK, Kim KM, Lee J. High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. J Cancer 2019; 10(14):3172-3178. doi:10.7150/jca.30257. https://www.jcancer.org/v10p3172.htm

CSE
Kim Y, Byeon Sj, Hur J, Lee K, Kim D, Ahn JH, Lee SH, You WK, Kim ST, Park SH, Kang WK, Kim KM, Lee J. 2019. High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. J Cancer. 10(14):3172-3178.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image